Powering precision immunology
Our platform brings together proprietary algorithms, the ImmunoEngine pipeline, and camyotope discovery into a unified workflow for antigen prediction and target prioritization — supporting the development of safer, more effective immune-based therapies. See how our platform powers our solutions across biologics and vaccine development.
Best-in-class predictive power
neoMS
Best-in-class HLA-agnostic presentation prediction algorithm that takes the full antigen processing pathway into account.
Read the paper →
neoIM
First-in-class immunogenicity prediction algorithm that accurately predicts the activation of CD4+ and CD8+ T-cells by a given epitope.
Read the paper →Best-in-class antigen discovery engine
Our computational ImmunoEngine platform combines deep whole-genomic and immunologic expertise with advanced AI-driven technologies. It enables smarter target discovery and prioritization — empowering vaccine developers, biologics innovators, and pharma partners to design safer, more effective immune-based therapies across indications.
The platform provides a robust, IVD-ready pipeline focused on the identification of antigen targets within the full genome of cells, outperforming the current state-of-the-art. Through analysis of WGS data, we uncover more and better targets — including dark targets such as camyotopes — enabling us to find actionable targets even in the lowest tumor mutational burden cancers.
Tapping into the dark genome
Through our deep expertise in whole genome target discovery, we explore the dark genome — an untapped source of (neo)antigens. Our unique technology has uncovered a novel source of dark targets, camyotopes, enabling a new approach for off-the-shelf immunotherapeutic development in solid tumors. See our internal programs advancing camyotope-based therapies to the clinic.
Unique characteristics
- Cancer exclusive
- High abundance
- Up to 95% patient coverage
- Up to 95% HLA coverage
- Validated expression & translation
- Validated MHC-I presentation
- Validated immunogenicity
Backed by peer-reviewed science
The ImmunoEngine platform is validated through peer-reviewed publications, technology papers, and whitepapers — covering neoantigen discovery, immunogenicity prediction, and cancer immunotherapy.
Browse all publications →